Key result
The direct renin inhibitor aliskiren attenuated the progression of liver fibrosis and hepatocarcinogenesis in a rat model of non-alcoholic steatohepatitis.
Why the study?
Does aliskiren prevent liver fibrosis development and hepatocarcinogenesis in a rat model of NASH?
Population
Choline-deficient L-amino acid-defined (CDAA) diet-induced rat NASH model
Design
Preclinical
Authors
Loading...
Should not change NASH practice; hypothesis-generating for renin inhibition in human fibrosis trials.
Does aliskiren prevent liver fibrosis development and hepatocarcinogenesis in a rat model of NASH?
The direct renin inhibitor aliskiren attenuates liver fibrosis and preneoplastic lesions in a rat model of NASH, suggesting a potential new therapeutic strategy.
Aihara et al. (2013) studied Non-alcoholic steatohepatitis (NASH). Aliskiren was evaluated on Progression of liver fibrosis and hepatocarcinogenesis. The direct renin inhibitor aliskiren attenuated the progression of liver fibrosis and hepatocarcinogenesis in a rat model of non-alcoholic steatohepatitis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: